dc.contributor.author | World Health Organization | |
dc.date.accessioned | 2012-06-17T01:07:51Z | |
dc.date.available | 2012-06-17T01:07:51Z | |
dc.date.created | 2003 | fr |
dc.date.issued | 2003 | fr |
dc.identifier.govdoc | WHO/HIV/2003.10 | fr |
dc.identifier.uri | http://www.who.int/iris/handle/10665/68673 | |
dc.description | WHO/HIV/2003.10 | fr |
dc.description | 1 p. | fr |
dc.language.iso | en | en |
dc.language.iso | fr | en |
dc.language.iso | es | en |
dc.publisher | Genève : Organisation mondiale de la Santé | fr |
dc.relation.ispartofseries | Treat 3 Million by 2005 Initiative technical briefs | fr |
dc.subject.mesh | HIV infections | fr |
dc.subject.mesh | Drug resistance, Microbial | fr |
dc.subject.mesh | Anti-retroviral agents | fr |
dc.subject.other | AIDS and its Control | fr |
dc.title | Comment le problème de la pharmacoréistance sera-t-il abordé dans le cadre de l' initiative "3 millions d' ici 2005" ? | fr |
dc.subject.meshqualifier | drug therapy | fr |
dc.subject.meshqualifier | therapeutic use | fr |
who.relation.languageVersion | 10665/68685 | en |
who.relation.languageVersion | 10665/68661 | en |